The TPD52L3 (Tumor Protein D52-like 3) antibody targets a protein encoded by the *TPD52L3* gene, a member of the Tumor Protein D52 family. This family is characterized by conserved coiled-coil domains and is implicated in regulating cell proliferation, apoptosis, and vesicular trafficking. TPD52L3 shares structural homology with other family members, including a putative SH2-binding domain, suggesting roles in signal transduction pathways. While less studied than TPD52 or TPD52L1. TPD52L3 has been linked to cancer biology, particularly in prostate and breast cancers, where its overexpression correlates with tumor progression and poor prognosis. It is thought to modulate cellular processes like exocytosis, membrane dynamics, and stress responses. Antibodies against TPD52L3 are primarily used in research to detect protein expression levels via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. These tools help elucidate its tissue-specific distribution, subcellular localization (e.g., Golgi or endosomal compartments), and interactions with binding partners. Recent studies also explore its potential as a diagnostic or prognostic biomarker. However, functional insights remain limited, necessitating further investigation into its mechanistic roles in normal physiology and disease contexts.